^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    detalimogene voraplasmid (EG-70)

    i
    Other names: EG-70
    Associations

    News

    Trials
    Company:
    enGene
    Drug class:
    Gene transference, IL-12 stimulant, RIG-I modulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve (clinicaltrials.gov)
    P1/2, N=222, Recruiting, enGene, Inc. | Trial completion date: Feb 2026 --> May 2027 | Trial primary completion date: Jul 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    detalimogene voraplasmid (EG-70)